Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Reactogenicity and Immunogenicity of a Bivalent Recombinant RSV Vaccine (SCB-1019T) in Children 2 to <6 Years of Age

NCT06666179 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals AUS Pty as lead sponsor.

NCT NCT06666179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06666179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Reactogenicity and Immunogenicity of a Bivalent Recombinant RSV Vaccine (SCB-1019T) in Children 2 to <6 Years of Age
Lead sponsor
Clover Biopharmaceuticals AUS Pty
Phase
Phase 1
Overall status
Withdrawn
Start date
October 31, 2025
Completion date
December 31, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rsv infection